Toulouse Cedex 9

• A study of pelabresib and ruxolitinib compared to placebo and ruxolitinib in adult patients with myelofibrosis who have not received prior t … Pending
  2025-523555-66-00 5 Myelofibrosis
• A Phase 1/2, Multicenter, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, a … Pending
  2025-523590-42-00 7 Locally Advanced or Metastatic Solid Tumors
• First adjuvant trial in locally resected aggressive pancreatic neuroendocrine tumors: a randomized phase III investigating the efficacy of s … Pending
  2025-523593-16-00 5 Pancreatic NeuroEndocrine Tumors (PanNET) ; Aggressive stage I-III wel
• Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending
  2025-523683-20-00 4 Postmenopausal patients with small (pT1a-b pN0) hormone receptor posit
• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat … Pending
  2025-523735-19-00 5 Metastatic Microsatellite Stable Colorectal Cancer
• Efficacy and safety of vamifeport in adult subjects with HFE-related hereditary hemochromatosis Pending
  2025-523793-16-00 4 Homeostatic iron regulator gene-related hereditary hemochromatosis
• A study in people with advanced extrapulmonary neuroendocrine cancer to compare obrixtamig plus carboplatin and etoposide treatment with sta … Pending
  2025-523869-22-00 5 advanced or metastatic extrapulmonary neuroendocrine carcinoma
• Liver-directed chemotherapy after surgery of liver metastases of colorectal cancer in patients with high risk of recurrence of their disease … Pending
  2025-523913-27-00 5 Participants with R0/R1 resected liver metastases from colorectal canc
• Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults with Advanced Colorectal Cancer. Pending
  2025-523984-39-00 4 Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
• Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ … Pending
  2025-524095-27-00 4 HER2-negative, unresectable, recurrent, and/or metastatic gastric, GEJ
• A study of cemsidomide and dexamethasone in subjects with relapsed or refractory multiple myeloma (r/r MM) Pending
  2025-524181-26-00 4 relapsed/refractory multiple myeloma
• TAILORswitch (PADA-2): rising ctDNA to tailor endocrine therapy switch in patients with ER+/HER2- metastatic breast cancer. Pending
  2025-524213-84-00 5 Patients with advanced or metastatic ER+ HER2- breast cancer
• Study of BMS-986353, CD19-CAR T Cells, versus SoC in Participants with Active SSc (Breakfree-SSc) Pending
  2025-524337-11-00 5 Systemic Sclerosis
• Achieve - ACetazolamide in patients with Heart failure, to decrease weight and relIEVE symptoms Pending
  2025-524344-35-00 5 Heart failure
• Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant r … Pending
  2025-524374-42-00 4 allogeneic haematopoietic stem cell transplant recipient
• A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic P … Pending
  2025-525009-18-00 5 Pancreatic Ductal Adenocarcinoma
• STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcera … Pending
  2026-525643-32-00 6 ulcerative colitis
• A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-523815-12-00 5 2026-07-06 Relapsed or Refractory Multiple Myeloma
• First-in-Human Trial of DS3610a in Participants with Advanced Solid Tumors Recruiting
  2025-521173-13-00 1 2026-07-01 Advanced Solid Tumors
• A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3) Recruiting
  2025-524404-29-00 4 2026-06-24 Ulcerative Colitis, Active Moderate
• A maintenance study to investigate the efficacy and safety of duvakitug in participants with moderately to severely active ulcerative coliti … Recruiting
  2025-521038-27-00 5 2026-06-23 Immune system diseases
• A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older with Locally Advanced or Metastatic … Recruiting
  2024-518871-74-00 4 2026-06-08 Locally Advanced or Metastatic Solid Tumours that harbour MET Amplific
• Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Recruiting
  2024-519994-20-00 5 2026-06-01 Agitation Associated with Alzheimer’s Disease
• Screening for subclinical antibody mediated rejection and efficacy of belatacept in the context of de novo donor specific antibody after kid … Recruiting
  2024-516527-13-00 11 2026-05-27 Kidney transplantation

Showing 73–96 of 906 trials